As with all industries, artificial intelligence is generating significant buzz in the clinical research space. But where does it offer meaningful impact today, and where is there still work to be done? In this session, we’ll explore the practical realities of applying AI tools within the context of electronic clinical outcomes assessment data, from operational efficiencies like study setup and translation to the future promise of patient-facing applications. Join us for an honest look at what’s achievable now, what’s emerging, and how to think strategically about this fast-moving future.
Archives: Agenda
Choosing the right CRO: key considerations for small biotechs
- Evaluating CRO capabilities and experience relevant to your specific therapeutic area and development stage
- Balancing cost, quality and timelines within tight budget constraints
- Negotiating contracts with flexibility to protect your biotech’s goals
CASE STUDY: What does it take to start up a biotech company from scratch?
- An overview of common challenges and how to overcome these
- Securing initial funding: navigating opportunities available to raise capital
- Overcoming early stage hurdles
- Building strategic partnerships to support your biotech
Studies Beyond Borders: Managing the logistics of conducting worldwide clinical trials
- Navigating global data restrictions: Lowering concerns and finding solutions regarding the limitations on research imposed by GDPR in the EU
- Sharing best practice for scaling studies across multiple states and countries despite a lack of consistency with regulations
- Looking at the intersection of data privacy and sample ownership regulations with the business imperative to address new questions that may arise during study analysis
- Addressing concerns at the protocol and ICF development phase
Implementing an EDC system: operational and technical considerations
- Considerations during EDC vendor selection
- Operational and technical considerations when implementing Patient Reported Outcomes measures
- Outsourced/Hybrid/Insourced EDC development models- cost and operational considerations
TECHNOLOGY SPOTLIGHT: The impact of Simulation-Based learning on Study Acceleration – Spoken from the Sponsor who converted
- What forced me to think strategically about clinical research training methodology
- Gaps & Risks of ‘check-the-box’ training
- Initial impact of Simulation-Based training on risk mitigation, Site time, Satisfaction, Enrollment and Quality
- Advances in Simulation-Based training that enhance site and patient engagement as well as optimize protocols
Harnessing real world experience: driving innovation and decision making
- Collecting and integrating supportive data sources for complimentary patient insights
- Understanding the regulatory landscape around RWE and how to navigate this efficiently
- Ensuring data quality, privacy and regulatory compliance in RWE initiatives
Opportunities in building AI models for efficiency in outsourcing
- Identifying outsourcing opportunities and pitfalls to avoid that can be addressed through AI driven solutions: timeline standards, document prep and system utilization
- Developing operationally, process and system driven AI models to support clinical operations and outsourcing: what can be streamlined?
- Integrating AI insights into outsourcing strategy to drive speed, quality and cost effectiveness: timelines, project management and reconciliation
PANEL: Patient advocacy and incorporating patient perspectives early on in a small biotech
- Developing relationships with advocacy groups and patient communities from early stages
- How does patient advocacy differ at biotechs vs large pharma?
- Integrating patient insights into your study to ensure patients remain the priority throughout your trial
MODERATOR Hollie Schmidt, Vice President, Scientific Operations, Accelerated Cure Project for MS